MX343620B - Forma polimorfica de clorhidrato de pridopidina. - Google Patents

Forma polimorfica de clorhidrato de pridopidina.

Info

Publication number
MX343620B
MX343620B MX2014002731A MX2014002731A MX343620B MX 343620 B MX343620 B MX 343620B MX 2014002731 A MX2014002731 A MX 2014002731A MX 2014002731 A MX2014002731 A MX 2014002731A MX 343620 B MX343620 B MX 343620B
Authority
MX
Mexico
Prior art keywords
polymorphic form
pridopidine
pridopidine hydrochloride
hydrochloride
polymorphic
Prior art date
Application number
MX2014002731A
Other languages
English (en)
Other versions
MX2014002731A (es
Inventor
Sonesson Clas
Pittelkow Thomas
Frostrup Brian
Zimmermann Anne
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of MX2014002731A publication Critical patent/MX2014002731A/es
Publication of MX343620B publication Critical patent/MX343620B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a una nueva forma cristalina de Pridopidina, una sustancia de fármaco actualmente en desarrollo para el tratamiento de la enfermedad de Huntington. Más específicamente la invención proporciona una Forma II polimórfica de la sal de clorhidrato de Pridopidina, un proceso para la preparación de esta forma polimórfica, composiciones farmacéuticas que comprenden la Forma II polimórfica y métodos de uso de esta forma polimórfica.
MX2014002731A 2011-09-07 2012-09-06 Forma polimorfica de clorhidrato de pridopidina. MX343620B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201170496 2011-09-07
US201161533550P 2011-09-12 2011-09-12
PCT/EP2012/067371 WO2013034622A1 (en) 2011-09-07 2012-09-06 Polymorphic form of pridopidine hydrochloride

Publications (2)

Publication Number Publication Date
MX2014002731A MX2014002731A (es) 2014-04-30
MX343620B true MX343620B (es) 2016-11-11

Family

ID=47831564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002731A MX343620B (es) 2011-09-07 2012-09-06 Forma polimorfica de clorhidrato de pridopidina.

Country Status (14)

Country Link
US (1) US9006445B2 (es)
EP (1) EP2753603B1 (es)
JP (2) JP6189299B2 (es)
KR (1) KR20140075703A (es)
CN (1) CN103958469B (es)
AU (1) AU2012306386B2 (es)
BR (1) BR112014005389A8 (es)
CA (1) CA2847736A1 (es)
EA (1) EA023462B1 (es)
ES (1) ES2639052T3 (es)
IL (1) IL231149A0 (es)
MX (1) MX343620B (es)
WO (1) WO2013034622A1 (es)
ZA (1) ZA201402492B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
EP4620471A3 (en) 2017-08-14 2025-11-26 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
EP3678664A1 (en) * 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GB0329236D0 (en) * 2003-12-17 2004-01-21 Arakis Ltd Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride
EP2204363A1 (en) 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
WO2006040155A1 (en) * 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
ES2528040T3 (es) 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
IN2015DN03219A (es) 2012-09-27 2015-10-02 Teva Pharma
WO2014052935A2 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Also Published As

Publication number Publication date
EP2753603B1 (en) 2017-06-21
BR112014005389A2 (pt) 2017-03-28
EA023462B1 (ru) 2016-06-30
EP2753603A1 (en) 2014-07-16
CN103958469B (zh) 2016-04-20
NZ623344A (en) 2015-10-30
AU2012306386B2 (en) 2017-06-15
MX2014002731A (es) 2014-04-30
JP6189299B2 (ja) 2017-08-30
KR20140075703A (ko) 2014-06-19
CA2847736A1 (en) 2013-03-14
JP2017206516A (ja) 2017-11-24
EA201490569A1 (ru) 2014-09-30
US9006445B2 (en) 2015-04-14
HK1199728A1 (en) 2015-07-17
CN103958469A (zh) 2014-07-30
WO2013034622A1 (en) 2013-03-14
IL231149A0 (en) 2014-04-30
BR112014005389A8 (pt) 2018-04-03
US20140315951A1 (en) 2014-10-23
ZA201402492B (en) 2015-07-29
ES2639052T3 (es) 2017-10-25
JP2014525470A (ja) 2014-09-29
AU2012306386A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
IN2014KN00948A (es)
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
IL218257A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating uses thereof
MY149731A (en) Compounds
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
MX2013012588A (es) Inhibidores de cinasa.
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX2013013465A (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX2013008197A (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
IN2013DN02555A (es)
EP2752202A4 (en) PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES, COMPOSITION FOR PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES, AND PROCESS FOR PRODUCTION OF PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"
IL230907A0 (en) Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them
EA201391743A1 (ru) Фармацевтическая композиция, содержащая дротаверин
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
IN2014DN10683A (es)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: GILEAD SCIENCES, INC.

FG Grant or registration